Alumis Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune and neuroinflammatory diseases. The company's pipeline centers on allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in immune signaling. ESK-001, its lead asset, is in clinical development for plaque psoriasis and systemic lupus erythematosus. A-005, a brain-penetrant TYK2 inhibitor candidate, targets neuroinflammatory and neurodegenerative conditions. The company also pursues interferon regulatory factor 5 (IRF5) inhibition to address immune dysfunction across multiple indications.
As a clinical-stage entity, Alumis does not generate product revenues. The company was incorporated in 2021 and operates from its headquarters in South San Francisco, California, with a workforce of 221 full-time employees. The organization changed its name from Esker Therapeutics to Alumis in January 2022.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-10.38 | $-10.38 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-19 | 0001847367-25-000012 | SEC ↗ |